Curative Biotechnology (Curative Biotechnology) Cash-to-Debt : 0.07 (As of Mar. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Curative Biotechnology Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Curative Biotechnology's cash to debt ratio for the quarter that ended in Mar. 2023 was 0.07.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Curative Biotechnology couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2023.

The historical rank and industry rank for Curative Biotechnology's Cash-to-Debt or its related term are showing as below:

CUBT's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.23
* Ranked among companies with meaningful Cash-to-Debt only.

Curative Biotechnology Cash-to-Debt Historical Data

The historical data trend for Curative Biotechnology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Curative Biotechnology Cash-to-Debt Chart

Curative Biotechnology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

Get a 7-Day Free Trial

N/A

0.29

No Debt

0.06

Curative Biotechnology Quarterly Data
	Dec16	Dec17	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Cash-to-Debt	Get a 7-Day Free Trial															1.99	0.22	-	0.06	0.07

Competitive Comparison of Curative Biotechnology's Cash-to-Debt

For the Biotechnology subindustry, Curative Biotechnology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Curative Biotechnology's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Curative Biotechnology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Curative Biotechnology's Cash-to-Debt falls into.

Curative Biotechnology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Curative Biotechnology's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.059	/	(1.071	+	0)
	=	0.06

Curative Biotechnology's Cash to Debt Ratio for the quarter that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.098	/	(1.369	+	0)
	=	0.07

Curative Biotechnology (OTCPK:CUBT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Curative Biotechnology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Curative Biotechnology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Curative Biotechnology (Curative Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curative Biotechnology Inc (OTCPK:CUBT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1825 NW Corporate Boulevard, Suite 110, Boca Raton, FL, USA, 33431

Website

https://www.curativebiotech.com

Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The company currently has ongoing programs in three therapeutic areas: Infectious Disease, Neuro-Oncology, and Degenerative Eye Disease.